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Abstract 
Recent research has suggested that endorphin systems may 
participate in the physiological regulation of feeding 
behavior in both normal and genetically obese animals. The 
purpose of this research was to both examine the effects of 
the opiate antagonist naloxone on feeding behavior and 
measure pituitary beta-endorphin-like immunoreactivity for 
each of several animal models of obesity. 
Adult female rats received ventromedial hypothalamic 
lesions (VMH), dorsolateral tegmental lesions (DLT), 
parasagittal hypothalamic knife cuts (KC), intraventricular 
injections of 5,7-dihydroxytryptamine (5,7-DHT), or control 
surgery (NWRA) , or were ovariectomized (OVX). All animals 
were maintained at normal body weight during testing except 
for an additional group of neurologically intact rats that 
was maintained at 75% of normal body weight (DEP). The 
effect of 0.5, 1.8, 6,8, and 25.0 mg/kg naloxone on the 
consumption of laboratory pellets was measured during 
four-hour daily access periods. Doses of 1.8, 6,8, and 25.0 
mg/kg caused successive significant decrements in food 
intake. Groups KC, 5,7-DHT, DLT, and VMH ate significantly 
more than group NHRA. Groups OVX and DEP did not eat more 
than NWRA. The Group x Dose interaction was not significant. 
Thus, while both naloxone dose and surgery had significant 
effects on food intake, no surgical group was more or less 
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sensitive to the effects of naloxone on food intake than any 
other. 
After completion of the naloxone tests half of each 
surgical group continued maintenance on pellets at normal 
body weights. The other half of each surgical group was 
allowed to feed ad libitum on a wet mash diet (70% water). 
Additional rats from the same original pool served as another 
control group. These rats had never received naloxone and 
had always had free access to laboratory pellets. Half of 
these rats continued on pellets ad libitum and half began 
free access to tha wet mash. After five weeks animals were 
sacrificed and pituitaries assayed for beta-endorphin-like 
immunoreactivity. Pellet-fed rats had slightly lower (11%) 
concentrations of beta-endorphin-like immunoreactivity than 
wet mash-fed rats. This effect appeared due to diet itself 
rather than differences in body weight or feeding regimen. 
Rats with hypothalamic knife cuts had significantly lower 
pituitary beta-endorphin-like immunoreactivity than all other 
groups. 
These results indicate: (1) that at lean body weights, 
feeding in the hyperphagia/obesity syndromes tested is not 
more or less sensitive to naloxone than in normal rats; (2) 
that elevated concentrations of beta-endorphin-like 
immunoreactivity are not related to hyperphagia in the 
syndromes examined; and (3) that obesity itself may have 
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little if any effect on pituitary beta-endorphin-like 
iramunoreactivity, 
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Introduction 
The recent discovery of two groups of peptides with 
opioid properties, the enkephalins and endorphins, has 
stimulated a flurry of varied research activities. In the 
four years since their discovery the possible roles of these 
substances in pain modulation (Cox, Goldstein, S Li, 1976; 
Graf, Szekely, Ronai, Dunai-Kovacs, S Bajusz, 1976), mental 
illness (Vereby, Volavka, & Clouet, 1978; Watson, Akil, 
Berger, S Barchas, 1979), sexual behavior (Gessa, Paglietti & 
Quarantotti, 1979), open field activity (Veith, Sandman, 
Walker, Coy, & Kastin, 1978), stress responses (Guillemin, 
Vargo, Rossier, Minick, Ling, Rivier, Vale, & Bloom, 1977) , 
the regulation of gut activities (Hughes, Smith, Kosterlitz, 
Fothergill, Morgan, & Morris, 1975; Jacques, 1977; Konturek, 
Pawlik, Walus, Coy, f> Schally, 1978; Konturek, Tasler, 
Cieszkowski, Jaworek, Coy, & Schally, 1978), and control of 
food intake (Grandison & Guidotti, 1977; Kenny, McKay, Woods, 
& Williams, 1978; Margules, Haisset, Lewis, Shibuya, S Pert, 
1978) have been examined. Investigations in the latter 
category have yielded intriguing results, and have suggested 
a role particularly for beta-endorphin (B-END) in both normal 
and abnormal feeding behaviors. 
B-END is contained in high concentrations in both the 
hypothalamus and pituitary (Bloom, Rossier, Battenbecg, 
Bayon, French, Henciksen, Siggins, Segal, Browne, Ling, & 
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Guillemin, 1978), There is suggestive evidence that B-END in 
both locations may play a role in feeding behavior. Kenny et 
al. (1978) reported that injection of 200 ng B-END into the 
lateral ventricle of the rat increased consumption of 
sweetened milk. This effect was not obtained with other 
peptides (cholecystokinin, substance P, neurotensin). 
Peripheral injection of the same dose of B-END was without 
effect. Grandison and Guidott.i (1977) demonstrated that 
intrahypothalaraic injection of 1.46 nm of B-END caused 
increased intake of laboratory chow. If the effects of B-END 
on feeding behavior are specific to opiate receptor 
activation, then drugs which prevent the binding of B-END to 
its receptors should block the effects of exogenous B-END. 
Grandison and Guidotti (1975) reported that intrahypothalaraic 
injection of naloxone, a drug known to compete "more 
successfully" than B-END for the same receptors, blocked the 
feeding behavior induced by B-END. 
Naloxone also suppresses the feeding behavior of intact 
animals. Holtzman (1974, 1975) reported that naloxone 
suppressed intake of laboratory pellets during feeding after 
48-hour food deprivation, and also decreased the intake of 
sweetened Enfamil in nondeprived rats. Diaz, Paul, Frenk, 
and Bailey (1978) found that naloxone inhibited intake of 
evaporated milk in rats whose total caloric and fluid intake 
consisted of one-hour access to the milk. Margules et al. 
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(1978) found that naloxone suppressed food intake of normal 
rats and mice on a two or four hour restricted access 
schedule. These data suggest that B-END, or some other 
endogenous substance which binds to the same receptors, has a 
role in normal feeding. 
Margules et al, (1978) also investigated the effects of 
naloxone on the food intake of genetically obese mice (ob/ob) 
and rats (fa/fa). Food intake of genetically obese animals 
was decreased to a greater degree than was that of lean 
littermates, and significant suppression of feeding was 
obtained with lower doses of naloxone in genetically obese 
animals than in lean littermates. The significance of the 
greater effect of naloxone in genetically obese animals was 
magnified by data showing that the genetically obese animals 
had concentrations of B-END in their pituitaries 75 to 80& 
higher than those of lean littermates. Hypothalamic B-END 
content of the obese rodents did not differ from lean 
littermates. 
The findings of Margules et al. (1978) clearly raise the 
possibility that actions of excessive pituitary B-END may be 
related to the exaggerated feeding of these genetically obese 
animals. Recent work by Ipp, Dobbs, and Dnger (1978) 
suggests a mechanism by which excessive B-END might cause 
greater than normal food intake. Ipp et al. (1978) reported 
that B-END causes release of insulin in vitro from isolated 
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pancreatic islets. This suggests a primary hyperinsulinemia 
as a mechanism in genetic obesity. Moreover, Beloff-Chain 
and colleagues (Beloff-Chain, Edwardson, S Hawthorn, 1975; 
Beloff-Chain & Hawthorn, 1976; Beloff-Chain, Hawthorn, 6 
Green, 1975) have shown that some material in pituitary 
perifusate causes in vitro release of insulin from pancreatic 
islets. Perifusates of pituitaries from genetically obese 
mice were more effective insulin secretagogues than 
perifusates from pituitaries of lean littermates. In 
summary, the above data suggest that B-END mechanisms may 
participate in the regulation of feeding behavior in both 
normal and genetically obese animals. One question raised by 
these data is the extent to which abnormalities in B-END 
systems may be associated with experimentally-induced 
obesities caused by central or peripheral interventions. 
There appear to be few data applicable to this question. 
Obesity can be induced by a number of interventions, 
including lesions of the ventromedial hypothalamus 
(Hetherington 6 Hanson, 1940), knife cuts between the medial 
and lateral hypothalamus (Sclafani, Springer, S Kluge, 1976), 
lesions of the dorsolateral tegmentum (Oltmans, Lorden, 6 
Margules, 1977; Peters, Gunion, G Wellman, 1979), 
intraventricular injection of 5,7-dihydroxytryptamine 
(5,7-DHT; Sailer 5 Strieker, 1976), and ovariectomy (Zucker, 
1969). No reports examining the effects of B-END antagonists 
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on feeding in these syndromes appear to exist, nor do data 
concerning pituitary B-END levels in these syndromes. Only 
two reports appear to bear on this question at all; both were 
investigations of the role of the pituitary in obesity 
development, York and Bray (1972) demonstrated that lesions 
of the ventromedial hypothalamus (VMM) induce overeating and 
obesity in both hypophysectomized and intact animals. 
Ahlskog, Hoebel, and Breisch (1974) examined pituitary 
involvement in obesity due to lesions of the dorsolateral 
tegmentum (DLT) and found that hypophysectomy blocked the 
development of this obesity. 
The reports of York and Bray (1972) and Ahlskog et al. 
(1974) suggest that VMH and DLT lesion syndromes may differ 
with respect to involvement of B-END, if abnormally high 
concentrations of pituitary B-END are indeed of importance in 
obesity development. VMH-lesioned rats might be expected to 
have normal levels of pituitary B-END, since the pituitary is 
not necessary for the development of VMH obesity. 
DLT-lesioned rats, however, might be expected to have 
elevated levels of pituitary B-END, since the pituitary is 
required for the development of this obesity. As a 
corollary, it might also be expected that the feeding of 
VMH-lesioned rats would be no more sensitive to the effects 
of naloxone than the feeding of normal rats, while the 
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feeding of DLT-lesioned rats would be significantly more 
suppressed. 
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Methods 
General_design 
The experiment described here was designed (1) to test 
the effect of naloxone on the feeding behavior of several 
experimental models of obesity, and (2) to see if any 
differences in pituitary B-END concentrations exist among 
these models. To avoid any confounding effects of obesity, 
animals were maintained at normal body weights throughout 
naloxone testing. After naloxone testing pituitaries were 
assayed for B-END content. The general course of the 
experiment was: 
1. surgery 
2. recovery 
3. test for naloxone effects on feeding 
4. maintenance until sacrifice. 
Groups. Five overeating/obesity syndromes were 
investigated. These were the syndromes due to: 
1. lesions of the ventromedial hypothalamus (VMH) 
2. lesions of the dorsolateral tegmentum (DLT) 
3. wire knife cuts in the parasagittal plane of 
the hypothalamic fornix (KC) 
U. intraventricular injection of 
5,7-dihydroxytryptamine (5,7-DHT), a neurotoxin 
having its primary effect on neurons containing 
5-hydroxytryptamine (serotonin) 
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5. ovariectomy. 
Each of these procedures has been shown to cause overeating 
and greater than normal body weight gain (Hetherington 5 
Ranson, 1940; Peters et al., 1979; Sclafani et al,, 1976; 
Sailer & Strieker, 1976; Zucker, 1969). 
Three control groups were included in this experiment: 
6. normal weight-restricted access (NWBA) -- this 
gLOup was allowed unlimited food during the 
restricted access periods 
7. 75% of normal weight (deprivation; DEP) — this 
group was given restricted amounts of food 
during the access periods, such that it was 
limited to 75% of its presurgical body weight 
8. free-feeding (FF) -- this group was allowed ad 
libitum access to food, and was never tested. 
The three control groups each served a different 
function. The NWRA group was treated almost exactly as the 
experimental groups, and was their most appropriate control. 
The difference in treatment was due to the necessity of 
restricting the amount of food available to some animals in 
the experimental groups. These animals would have gained 
excessive amounts of weight if allowed unlimited food even 
for the relatively brief access periods. The Ff group served 
as a control for any effects of a temporally restricted 
feeding schedule; by comparing the free-feeding group with 
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the normal weight-restricted access group, any changes in 
B-END levels due strictly to the feeding regimen could be 
made evident. The DEP group served as a control for any 
effect of continued "deprivation" of experimental animals 
relative to the elevated postsurgical weights they would have 
maintained if their food intakes were not restricted. 
Comparison of group DEP with group NHRA was intended to show 
any effects due to this relative deprivation of the 
experimental groups. 
Testing sequence. Rats were divided into three squads 
for drug tests. Each surgical group was represented 
approximately equally in each squad. Each squad was tested 
every third day, allowing each squad two days between tests. 
Each animal was tested once with each dose of naloxone 
HCl (0.5, 1.8, 6.8, and 25.0 mg/kg, ip), and received four 
saline tests. The lowest naloxone dose (0.5 mg/kg) is the 
lowest dose found effective in suppressing the food intake of 
lean rats by Hargules et al, (1978). The highest dose (25,0 
mg/kg) was chosen because preliminary work indicated lower 
doses (1,0 and 5,0 mg/kg) had little effect on feeding in 
normal animals in this laboratory. The two middle doses (1,8 
and 6,8 mg/kg) divide the 0,5 to 25,0 mg/kg range into 
logarithmically equal intervals. 
The total of eight tests for each rat was divided into 
four drug-saline pairs; that is, tests 1 and 2 constituted 
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one pair, tests 3 and 4 another pair, and so forth. This 
design was employed to allow appropriate analysis in the 
event that meaningful effects of repeated testing appeared. 
Whether the saline test paired with each naloxone test 
occurred on the first or second test day of each pair was 
random within the restrictions that: 1) on each test day 
approximately half of each surgical group was tested with 
saline, and half with naloxone; 2) no animal had exactly 
alternating naloxone and saline tests throughout the 
experiment (e.g. naloxone, saline, naloxone, saline, ...). 
Order of dose presentation was random within the restrictions 
that: 1) for no two rats in the same surgical group did two 
drug doses occur in the same order; 2) as far as possible, no 
two rats in the same surgical group were tested with the same 
dose on the same day. 
Subjects 
The subjects were female Long-Evans hooded rats (Blue 
Spruce Farms, Altamont, N.Y.) weighing 216 to 258 g at the 
beginning of the experiment. They were individually housed 
in standard hanging wire-mesh cages in a temperature 
controlled room (23 degrees C) under a 12/12 h light/dark 
cycle. During the dark portion of the cycle the room was 
illuminated by red light. Prior to surgery all animals had 
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free access to Teklad Mouse and Rat Pellets (Teklad, 
Winfield, Iowa). 
Surgiçal_Eçoçedures 
Lesion, knife cut, and ovariectomized animals were 
anesthetized with 30 mg/kg sodium secobarbital ip (Myothesia, 
Beecham). Methyl scopolamine (10 mg/kg ip) was given to 
decrease respiratory secretion. Rats receiving 
intraventricular injections were lightly anesthetized with 
sodium secobarbital and brought to surgical anesthesia with 
ether. NWRA and DEi" animals were lightly anesthetized with 
ether. All lesions were made using a stainless steel 
electrode insulated except for its 0.5 mm conical tip. 
Individual surgical procedures are described below. 
VMM lesions. Bilateral VMH lesions were made with the 
tip of the electrode positioned 0.5 mm above the base of the 
brain, 5.8 mm anterior to the interaural line, and 0.7 mm 
lateral to the midline, with the incisor bar 5.0 mm above the 
interaural line. Lesions were produced by passing 2.0 mA 
anodal current for 20 s between the electrode and a rectal 
cathode. 
DLT lesions. Bilateral lesions in the dorsolateral 
tegmentum were made with the incisor bar set 2.9 mm below the 
interaural line. The tip of the electrode was positioned 2.3 
mm anterior to the interaural line, 1.5 mm lateral from the 
midline, and 3.0 mm above the interaural line. Lesions were 
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produced by passing 0.75 mA cathodal current for 20 s between 
the electrode and a rectal anode. 
Knife cuts. Bilateral parasagittal cuts were made with 
a wire knife constructed after Hamilton and Timmons (1975) 
but not spring-loaded. The extended length of the wire blade 
was 3.0 mm. The incisor bar was set 5.0 mm above the 
interaural line. The knife, wire blade retracted, was 
lowered to approximately the level of the fornix (5.0 mm 
above the interaural line), 8.0 mm anterior to the interaural 
line and 1.0 mm lateral to the midline. The wire blade then 
was extended, the knife was lowered to the floor of the 
calvarium, and was raised to its original position. This 
down-and-up movement was repeated twice. The wire blade then 
was retracted, and the knife was withdrawn from the brain. 
5.7-DHT injections. Intraventricular injections of 
5,7-DHT consisted of 200 micrograms (free base) 5,7-DHT 
creatinine sulfate (Regis Chemical Company) dissolved in 0.1% 
ascorbic acid-normal saline vehicle. The injection volume of 
20 microliters was delivered at 10 microliters per minute. 
The injection needle was left in place for one minute 
post-injection to allow for further diffusion of the 
neurotoxin. Injections were made with the needle tip 
positioned 0.5 mm posterior to bregma, 1.7 mm lateral to the 
midline, and 4.0 mm below the skull surface; the incisor bar 
was 5,0 mm above the interaural line, Desmethylimipramine 
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(Pertrofane, USV, 25 mg/kg ip) was injected 40 to 60 minutes 
prior to 5,7-DHT injection to diminish cytotoxic action in 
nonserotonergic neurons (Baumgarten, Klemm, Lachenmayer, 
Bjorklund, Lovenberg, 5 Schlossberger, 1978). Motor 
seizures, when they occurred, were controlled by giving 
additional sodium secobarbital to effect. 
Ovariectomy. Ovaries were removed through bilateral 
dorsolateral incisions through the abdominal skin and muscle 
wall. A ligature vas placed below the ovary before the ovary 
and a portion of the uterine horn were removed. The muscle 
wall was sutured closed and the skin was closed with wound 
clips. 
Control surgery. Control surgery was performed on NHRA 
and DEP rats by lightly anesthetizing the animal, incising 
the scalp, and closing the wound. 
Proced ure 
Post-surgical procedure. Prior to surgery all animals 
had free access to laboratory pellets. All operated animals 
were food and water deprived for 18 to 24 hours after 
surgery. FF rats, which were never operated upon, were 
deprived of food and water for 24 hours during the four-day 
surgical period. FF rats otherwise had ad libitum access to 
food and water throughout the experiment. The procedure 
outlined below is for all groups except FF. 
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After post-surgical deprivation each rat was given free 
access to food for 24 hours and to water for the remainder of 
the experiment. Following free access to food for 24 hours, 
each rat operated upon during the first three surgical days 
was placed on a feeding schedule allowing 24 hour access to 
only enough food to maintain the animal near its presurgical 
body weight. This procedure was employed to prevent 
hyperphagia and excessive weight gain. All rats then began a 
two-hour restricted access schedule. Each animal was allowed 
two hours access to enough food to maintain that animal at 
its presurgical body weight if all the food was consumed 
(except DEP rats; see below). Food remaining at the end of 
the two-hour period was removed from the cage. Hats operated 
upon on the fourth (last) surgical day went directly from 
24-hour free access to two-hour restricted access. With the 
start of the two-hour restricted access feeding schedule, DEP 
rats were gradually reduced to 75% of their presurgical body 
weight by allowing them more limited amounts of food than 
available to other groups. After four days of two-hour 
restricted access, the duration of the access period was 
increased to four hours for all groups, and remained four 
hours throughout the testing period. All rats in the 
experimental groups were allowed, throughout the experiment, 
to weigh the same percentage of their presurgical body weight 
as the mean percentage of presurgical weight maintained by 
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the NWRA rats» As NWHA weights increased during the course 
oC the experiment due to normal growth, the same percentage 
increases were allowed in the experimental groups, DEP rats 
were allowed 75% of these increases. 
Drug testing. Naloxone effects on food intake were 
tested beginning 20 days after the last surgery. Daily 
procedure began with weighing all except FF rats. Following 
this the appropriate amount of food to maintain all rats not 
tested that day was determined. Appropriate injections then 
were given to the squad to be tested. Food was weighed for 
the test squad; once all food for this squad had been weighed 
it was delivered onto the cage floors, commencing the 
four-hour feeding period for this squad. The feeding period 
began approximately 15 minutes after the last injection. The 
food for the remaining two squads was then weighed and 
delivered. lour hours after the beginning of the test period 
food was withdrawn from the cages of the test squad; any food 
remaining in the cages of the squads not tested that day also 
was removed four hours after they had received their ration. 
Food intake to the nearest 0.1 g was determined for the test 
squad by subtracting the amount of food remaining at the end 
of the test period and spillage collected from under the cage 
from the amount of food delivered at the beginning of the 
test period. The four-hour feeding periods occurred over the 
fourth, fifth, sixth, and seventh hours of the dark period. 
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Beginning two days after the last naloxone test, all 
groups were divided in half such that the mean saline test 
intakes of each half was approximately the same, and the 
range of intakes in the entire group was reflected in each 
half as far as possible. One half of each group was randomly 
chosen to continue maintenance on the four-hour restricted 
access schedule. The other half of each group began ad 
libitum maintenance on a wet mash diet made of 70% tap water 
and 30% Wayne Lab Blox. The wet mash diet was employed to 
promote weight gain and the development of hyperphagia (e.g. 
Peters, Mellman, S Gunion, 1979). Wet mash was delivered 
fresh every 24 hours in glass ointment jars (81 mm high by 70 
mm wide) placed in the cage, and held to the cage front by a 
wire loop. Body weight aud 24-hour food intake of the rats 
fed the wet-mash diet were measured every three days for 36 
days. The wet mash given on day 11 was prepared with too 
much water. For this reason food intake on day 12 was not 
measured. 
Beginning 33 days after the last naloxone test, animals 
maintained on the restricted access feeding schedule were 
sacrificed. Animals fed the wet mash diets were sacrificed 
beginning 39 days after the last naloxone test. 
Be]^%endorBbin_assaY 
The rats were sacrificed by decapitation. Operated 
brains were removed and saved in 10% Formalin for histology. 
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Pituitaries were removed, gently blotted with a laboratory 
wipe, and weighed to the nearest 0.1 mg. Pituitaries were 
then placed in separate 50 ml polyethylene (Nalgene) 
centrifuge tubes containing 2.0 m], of hot 1 N acetic acid. 
The tubes were immersed in a boiling water bath. After 15 
minutes the tubes were removed from the bath and chilled in 
ice; when cold the tissue was ground in the same tube using a 
motor-driven Teflon pestle. The tube was allowed to stand in 
ice until centrifuged at 1200 x g for 50 to 70 minutes. The 
clear supernatant was saved and stored at -15 degrees C. 
The frozen supernatant was freeze-dried for 48 hours and 
stored at -15 degrees C until assay. The extract was 
prepared for assay by reconstitution with 2.0 ml of cold 
buffer (0.1 M puosphate at pH 6.0, 0.005 W EDTA, 0.05 M NaCl, 
5.0% mannitol, 0.1# gelatin, and 0.005% merthiolate). The 
tube was vortexed and allowed to stand on ice for 15 minutes. 
The extract was not completely solubilized, and the tube was 
centrifuged 15 minutes at 800 x g. One-tenth ml of the clear 
supernatant was used for assay of B-END content. B-END 
content was measured with a commercially available 
radioimmunoassay kit (New England Nuclear, Boston, NEK-003). 
The buffer used for reconstitution duplicated that supplied 
with the assay kit. 
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Histoloai 
Brains saved at sacrifice were stored in 10% Formalin 
until frozen sections (100 microns) were taken in the coronal 
plane. Photographic enlargements of these unstained sections 
were used to assess the location and extent of tissue damage, 
with reference to the atlas of Konig and Klippel (1963). 
Statistical analysis 
The effects of naloxone on food intake were analyzed 
both as intake in grams and as percentage decrease from the 
mean of the saline control tests. Analysis of variance 
(ANOVA) was followed by a posteriori evaluation using the 
Duncan New Multiple Range Test (Kirk, 1966) where warranted. 
Food intake and body weight data of rats fed the wet mash 
diet were also analyzed using ANOVAs followed by the Duncan 
New Multiple Range Test. All rats had a missing value for 
food intake on day 12 of wet mash consumption. Initial 
analysis of the assay data was done by regression, and was 
followed by the Duncan New Multiple Range Test. 
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Results 
Histoloai 
Examples of the destruction caused by VHH lesions, 
hypothalamic knife cuts, DLT lesions, and 5,7-DHT injections 
are shown in Figure 1. 
VHH lesions. (Figure la). VHH lesions generally 
destroyed the area posterior to the anterior nucleus, rostral 
to the premammillary nuclei, ventral to the dorsomedial 
nucleus, and medial to the fornix. There was a strong 
tendency for the lesions to include the premaramillary nuclei 
and heavily damage the mammillary bodies as well. In most 
cases there was little or no damage to the anterior nucleus. 
The lesion usually spread laterally to include the fornix 
within its border, and often, but not always, spread slightly 
lateral to the fornix. Four rats were discarded from this 
group for failure to meet the preceding description; in 
general, their lesions were quite posterior and spared much 
of the rostral portions of the VMH. 
Knife cuts. (Figure lb). The cuts began rostrally at 
the level of the optic chiasm. At this level, the cuts 
extended vertically from the fornix to the optic chiasm or, 
in a few cases, through the lateral portion of the optic 
chiasm. At the caudal edge of the anterior nucleus the cuts 
extended from the fornix to the base of the brain. This 
vertical plane encompassed approximately the rostral 
Figure 1. Photomicrographs of representative 
sections showing damage caused by: 
(a) ventromedial hypothalamic lesions 
(b) hypothalamic knife cuts (arrows point to 
cuts) 
(c) dorsolateral tegmental lesions 
(d) intraventricular 5,7-dihydroxytryptamine 
(arrow points to injection needle track). 
Figure 1. Photomicrographs of representative 
sections showing damage caused by: 
(a) ventromedial hypothalamic lesions 
(t) hypothalamic knife cuts (arrows point to 
cuts) 
(c) dorsolateral tegmental lesions 
(d) intraventricular 5,7-dihydroxytryptamine 
(arrow points to injection needle track). 
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two-thirds of the ventromedial nucleus (VMN); at this point 
both the dorsal and ventral extent of the cut began to rise. 
Cuts typically terminated ir the premammillary nuclei. At 
this level the cuts extended between the maminillothalamic 
tract and the fornix. The cuts lay in or very near the 
parasagittal plane of the fornix; several times the wire 
blade had been deflected by the fornix. The third ventricle 
often was slightly enlarged. Three rats were discarded from 
this group. Two had substantially enlarged ventricles, and 
one had a cut that did not reach the base of the brain at the 
level of the rostral VMN. 
DLT lesions. (Figure 1c). The location and extent of 
the DLT lesions were as recently described (Peters, Gunion, & 
Wellman, 1979). These cathodal lesions appear as thin 
vertical slits with dorsal extents adjacent to the 
ventrolateral edge of the periaqueductal gray, and ventral 
extents to the level of the superior cerebellar peduncle. 
Rostrally, the lesions begin within the exiting fibers of the 
oculomotor nerve and continue caudally as far as the 
decussation of the superior cerebellar peduncle. One rat was 
discarded because one of its lesions was too lateral. 
5.7-DHT injections. (Figure Id). A discernible 
injection needle track through the cortex and into the 
lateral ventricle was generally visible. Some damage to the 
dorsal hippocampus was evident in a number of animals. All 
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animals but one showed vibrisseal vibration at injection, and 
in many animals the pinnae folded caudally, flat against the 
head. These effects began approximately 30 seconds after the 
end of injection. One animal was discarded from this group. 
This animal did not show vibration of the vibrissae at 
injection, and the ventricle receiving the injection was 
grossly enlarged. The absence of behavioral signs and the 
enlarged ventricle suggest that, for some unknown reason, the 
injection volume may not have immediately passed out of the 
lateral ventricle. 
Final group size. In addition to loss by histology, two 
animals died after surgery. One animal from group 5,7-DHT 
died on the day after surgery shortly after access to food 
and water. Tt appeared healthy when food and water were 
delivered. One animal from group OVX died several weeks 
after surgery for unknown reasons. 
Final group sizes were 13 for DLT, 10 for 5,7-DHT, 11 
for KC, 11 for OVX, 12 for DEP, 12 for NWRA, 12 for FF, and 
10 for VMH. 
Nalox&ne_effects_on_food_intake 
Analyses of variance (ANOVAs) first were performed on 
intakes during the four saline tests to examine the effects 
of repeated testing. One between factor (Group) and one 
within factor (Test) were analyzed. As expected. Group was 
significant (F 6, 72 = 7.60; p < .0001), but Test was not (F 
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3, 216 = 1.30; p = ,275), In a further examination for 
effects of previous testing, the first saline test data were 
split into two groups: those animals for which the first of 
the eight total tests was saline, and those animals for which 
the first saline test was preceded by a naloxone test. 
Again, Group was significant (F 6, 65 = 6.17; p < ,0001) 
while Test was not (F 1, 65 = 0.52; p = .U74), It was 
concluded that there was no effect of saline test order. The 
four saline test values were averaged to obtain one value for 
the saline value that was used in all subsequent analyses. 
Naloxone effects were analyzed both as grams intake and 
as percentage change in intake. When analyzed as grams 
intake, both Group (F 6, 72 = 7.70; p < ,0001; Figure 2a) and 
Dose (F 4, 287 = 55.19; p < ,0001; Figure 2b) were 
significant. The Group x Dose interaction, however, was not 
significant (F 24, 287 = 1,18; p = ,259; Figure 3a), Thus, 
while both naloxone dose and surgical group had significant 
effects ou food intake, no surgical group was more or less 
sensitive to the effects of naloxone on food intake than any 
other. 
Table 1 and Figure 2a show the mean food intake of each 
surgical group averaged across dose, Duncan's New Multiple 
Range Test (Kirk, 1968) was used to compare mean intakes of 
the groups. Groups KC, 5,7-DHT, DLT, and VMH ate 
significantly more than group KWBA (all p < ,01) , while 
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Table 1. Surgical group mean intakes + S.E. (g) . See text 
for group abbreviations. Results of statistical 
comparisons are shown beneath the data: numbers 
are p values, ns means not significant. 
G£0U£ Intake 12.1 
KC 17. 1 + 0. 3 
5,7-DHT 16.0 + 0.5 
DLÏ 15.9 + 0.4 
VMH 15.6 + 0.6 
OVX 13.5 + 0. 3 
DEP 12.5 + 0.4 
NWRA 12.0 + 0. 3 
Comparisons 
KC versus VMH versus 
5,7-DHT ns OVX ns 
DLT ns DEP .01 
VMH us NWRA .01 
OVX .01 
DEP .01 
NWRA .01 
5,7-DHT versus OVX versus 
DLT ns DEP ns 
VMH ns NWRA ns 
OVX ns 
DEP .01 
NWRA .01 
DLT versus DEP versus 
VMH ns NWRA ns 
OVX ns 
DEP .01 
NWRA 0 1  
Figure 2, Food intakes during naloxone testing. 
(a) Main effect of surgical group on grams 
of food consumed during testing. Groups 
(see pp 9-10 for further explanation): 
DEP -- deprived to 75% of normal weight 
DLT -- dorsolateral tegmental lesion 
5,7-DHT -- intraventricular 
5,7-dihydroxytryptamine 
KC -- hypothalamic knife cut 
NWSA -- normal weight, restricted access 
OVX -- ovariectomy 
VMH -- ventromedial hypothalamic lesion. 
Main effect of naloxone dose on grams of 
food consumed during testing. 
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groups OVX and DE? did not (both p > .05). Groups KC, 
5,7-DHT, DLT, and VMM ate significantly more than DEP (all p 
< .01), but only group KC ate significantly more than OVX (p 
< .01; all others p > .05). Groups KC, 5,7-DHT, DLT, and VMH 
did not eat significantly different amounts (all p > .05). 
Table 2 and Figure 2b show the mean intake at each dose of 
naloxone, averaged across group. Doses of 1.8, 6.8, and 25.0 
mg/kg significantly decreased intake (all p < .01); only 0.5 
rag/kg did not (p > .05). Further, each of the three 
effective doses caused significantly greater suppression than 
the next lower dose (p < .05 for 0.5 versus 1.8; others, 
p < .01) . 
When the data were analyzed as percentage change in 
intake. Group was not significant (F 6, 72 = 1.24; p = .627). 
Dose was significant (F U, 287 = 56.08; p < .0001; Table 3), 
while the Group x Dose interaction was not (F 24, 287 = 1.26; 
p = .299; Figure 3b). Table 3 shows the mean percentage of 
saline intake at each dose. Comparisons among means showed 
exactly the same differences to be significant and 
nonsignificant as were found when the data were analyzed 
simply as mean grams intake. Significance levels also were 
unaltered. 
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Table 2. Mean intake + S. E. at each dose of naloxone. 
Results of statistical comparisons are shown 
beneath the data: numbers are p values, ns means 
not significant. 
Dose Jmg^kgl Intake 13.1 
0.0 15.9 + 0. 3 
0.5 15.6 + 0.4 
1.8 15.0 + 0.4 
6.8 13.8 + 0.4 
25.0 12.7 + 0.4 
Comparisons 
0.0 versus 
0.5 ns 
1 . 8  . 0 1  
6 . 8  . 0 1  
25.0 .01 
0.5 versus 
1.8 .05 
6 . 8  . 0 1  
25.0 .01 
1.8 versus 
6 . 8  . 0 1  
25.0 .01 
6.8 versus 
25.0 .01 
Figure 3, Effect of naloxone dose on food consumption 
during testing: 
(a) in grams of food consumed 
(b) as a percentage of the amount of food 
consumed during saline (0.0 mg/kg) tests. 
Groups (see pp 9-10 for further 
explanation): 
• DEP -- daprivad to 15% of normal weight 
O DLT -- dorsolateral tegmental lesion 
• 5,7-DHT -- intraventricular 
5,7-dihydroxytryptamine 
• KC — hypothalamic knife cut 
X NWBA — normal weight, restricted access 
o OVX -- ovariectomy 
V V M H  -- ventromedial hypothalamic lesion 
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Table 3. Percent of saline test intake + S. E. at each 
dose of naloxone. Results of statistical 
comparisons are shown beneath the data: numbers 
are p values, ns means not significant. 
Dose 
0 . 0  
0.5 
1 . 8  
6 . 0  
25.0 
Percentage Intake 
100 .0  
98. 2 
94.4 
86.4 
79.6 
0 . 0  
1.5 
1.4 
1.5 
1 . 2  
Comparisons 
0,0 versus 
0.5 ns 
1.8 .01 
6.8 .01 
25.0 .01 
0.5 versus 
1.8 .05 
6.8 .01 
25.0 .01 
1.8 versus 
6.8 .01 
25.0 .01 
6.8 versus 
25.0 .01 
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leta::endor£hin_dssai 
The manufacturer of the assay kit (New England Nuclear) 
states that the kit B-END antibody has 100% cross-reactivity 
with B-END and 50% cross-reactivity with beta-lipotropin. 
Alpha-endorphin, leu-enkephalin, met-enkephalin, 
alpha-melanocyte stimulating hormone, and 
adrenocorticotropic hormone are said to show less than 0.01% 
cross-reactivity to this antibody. Bloom, Rossier, 
Battenberg, Bayon, French, Henriksen, Siggins, Segal, Browne, 
Ling, and Guillemin (197B) have reported that, using gel 
chromatography and an antibody having 100% cross-reactivity 
to both B-END and beta-lipotropin, approximately 67% of the 
total immunoreactivity of rat whole pituitary extract can be 
attributed to B-END and the remaining 33% to beta-lipotcopin. 
It follows, then, that the total B-END-like immunoreactivity 
found by the assay kit in rat whole pituitary extract should 
be approximately 83% B-END and 17% beta-lipotropin. B-END 
concentrations determined in this experiment, then, reflect a 
contribution from beta-lipotropin. To avoid confusion, 
values are expressed here as picograms of beta-endorphin-like 
immunoreactivity (B-ENDLI) per milligram of wet pituitary 
tissue. 
All samples assayed on the first day, as well as the 
standard curve, were lost due to the addition of insufficient 
amounts of tracer. This left the DEP-wet mash cell with an n 
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of two, the FF-pellet cell with an n of three, and the 
NWRA-pellet cell with an n of four. All other cells had 
five to seven animals each. 
Additional total counts, blank, and zero standard tubes 
were run and values from these tubes used to determine the 
normalized percent bound for the remaining samples. The 
"technical data" standard curve supplied with the kit was 
used to determine the B-ENDLI content of the samples. This 
approach was considered acceptable, since previous work with 
these kits had repeatedly produced standard curves highly 
similar to those supplied. B-ENDLI content of samples 
determined in this manner were well in line with previous 
work using these kits. Using this method, sample aliquots 
diluted to half concentration before assay showed B-ENDLI 
contents half those of the undiluted samples. 
Because of loss of some samples at assay, cell n's were 
too unequal for ANOVA. Consequently, regression (partial 
sums of squares) was used to analyze the B-ENDLI 
concentration (pg/mg wet weight) data. The main effect of 
Group was significant (F 7, 60 = 5.08; p < .0003; Table 4; 
Figure 4a), as was the main effect of Diet (F 1, 60 = 4.63; 
p < .03; Figure 4b). The mean values of B-ENDLI ranged from 
23.1 pg/mg to 71,6 pg/mg among the surgical groups. For the 
two diets the means were 51.0 pg/mg for animals sacrificed at 
restricted weight (pellet diet), and 58.7 pg/mg for animals 
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Table U, Surgical group mean + S. E. concentrations 
of pituitary beta-endorphin-like immunoreactivity 
(pg/mg wet weight). See text for group 
abbreviations. Results of statistical comparisons 
are shown beneath the data: numbers are p values, 
ns means not significant. 
EbBNDLi ifiaznal. 
DEP 71.6 + 4.9 
DLT 63.0 + 7.1 
VMH 59.6 + 7.9 
NWRA 59.5 + 7.3 
OVX 56.0 + 7.5 
FF 55.4 + 7.8 
5,7-DHT 47.9 + 3.5 
KC 23.1 + 3.5 
Comparisons 
DEP versus NWRA versus 
DLT ns OVX ns 
VHH ns FF ns 
NWRA ns 5,7-DHT ns 
OVX ns KC .01 
FF ns 
5,7-DHT .05 
KC .01 
OVX versus 
DLT versus FF ns 
VMH ns 5,7-DHT ns 
NWRA ns KC .01 
OVX ns 
FF ns 
5,7-DHT ns 
KC .01 FF versus 
5,7-DHT ns 
VHH versus KC .01 
NWRA ns 
OVX ns 
FF ns 
5,7-DHT ns 5,7-DHT versus 
KC .01 KC .01 
Figure U. Pituitary beta-endorphin-like immunoreactivity 
concentrations. 
(a) Main effect of surgical group on 
concentration of pituitary 
beta-endorphin-like immunoreactivity 
(pg/rag) . 
Groups (see pp 9-10 for further 
explanation): 
DEP -- deprived to 75% of normal weight 
DLT — dorsolateral tegmental lesion 
5,7-DHT -- intraventricular 
5,7-dihydroxytryptamine 
FF — free feeding 
KC -- hypothalamic knife cut 
NWRA -- normal weight, restricted access 
OVX -- ovariectomy 
VMM -- ventromedial hypothalamic lesion. 
(1)) Main effect of feeding regimen at 
sacrifice on concentration of pituitary 
beta-endorphin-like immunoreactivity 
(pg/rag). Pellet (4-hour access) rats 
were sacrificed at normal body weight. 
Wet mash (ad lib.) rats were sacrificed 
at free-feeding body weight. 
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sacrificed at ad libitum weight (wet mash diet). The Group 
X Diet interaction was not significant (F 7, 60 = 0.76; 
p = .627) . 
Duncan's New Multiple Range Test (Kirk, 1968) was used 
to further examine the effect of Group on B-ENDLI 
concentrations (Table 4). The concentration of 3-ENDLI for 
group KC (23.1 mg/kg) was significantly less than that of 
each of the other groups (mean of 59.8 pg/mg across these 
groups; all p < .01). Additionally, 5,7-DHT (47.9 pg/mg) had 
significantly less B-ENDLI than DEP (71.6 pg/mg; p < .05). 
No other differences were significant. 
The significantly lower concentration of pituitary 
B-ENDLI in 5,7-DHT rats when compared to DEP rats is 
puzzling. This difference does not appear to have any 
relationship with the general pattern of results of this 
work. Neither DE? nor 5,7-DHT groups differed significantly 
from the NWBA or FF control groups. It should be considered 
here that the difference between DEP and 5,7-DHT was 
significant only at the .05 level; in fact, had the mean 
difference of 23.7 pg/mg been just 3,2 pg/mg less, the 
difference would not have been significant at all. At 
present the significant difference in pituitary B-ENDLI 
concentrations between groups 5,7-DHT and DEP seems cost 
reasonably interpreted as Type I (alpha) error, and it will 
not be further discussed. 
Figure 5. Group mean body weights of animals allowed ad 
libitum access to the wet mash diet after the 
end of naloxone testing. Group ns are shown 
in the key. 
Groups (see pp 9-10 for further explanation): 
DEP — deprived to 75% of normal weight 
OLÎ — dorsolateral tegmental lesion 
5,7-DHT -- intraventricular 
5,7-dihydroxytryptamine 
FF — free feeding 
KC — hypothalamic knife cut 
NWEA -- normal weight, restricted access 
OVX -- ovariectomy 
7MH — ventromedial hypothalamic lesion. 
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Figure 5 shows the changes in body weight that occurred 
during the first 36 days ad libitum access to the wet mash 
diet. ANOVA showed significant effects of Group (F 1, 37 = 
27.78; p < .0001), Day (F 11 , 407 = 458.77; p < .0001), and 
Group X Day (F 11, 407 = 45. 81 ; p < .0001). Analyses of 
group mean body weights on day 36 revealed that body weights 
formed three distinct clusters. A "very obese" cluster 
consisted of groups VMH and KC; a "moderately obese" cluster 
consisted of groups DLT and OVX; and a "normal weight" 
cluster consisted of groups 5,7-DHT, NWRA, DEP, and FF. 
Within each cluster, no group weighed significantly more or 
less than any other group (ail p > .05). All other 
comparisons (that is, those made between groups from 
different clusters) were significant (DLT versus 5,7-DH, p < 
.05; DLT versus FF, p < .05; all others, p < .01); see Table 
5). 
The food intake data paralleled the body weight data 
(see Figure 6). Again, ANOVA showed significant effects of 
Group (F 7, 37 = 53.33; p < .001), Day (F 10, 370 = 36.73; 
p < .0001), and Group x Day (F 70, 370 = 9.13; p < .0001). 
The main effect of surgical group on wet mash consumption is 
shown in Table 6. All groups (KC, VMH, OVX, DLT) which 
weighed significantly more than group NWRA on day 36 also ate 
significantly more than NWHA over the 36 day period (OVX 
versus NWRA, p < .05; all others, p < .01). Groups (5,7-DHT, 
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DEP, FF) that did not have weights significantly different 
from NWRA on day 36 did not eat amounts significantly 
different from NWRA (all p > ,05). 
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Table 5. Group mean body weights + S. E, (g) on day 36, 
See text for abbreviations. Results of 
statistical comparisons are shown beneath the 
data: numbers are p values, ns means not 
significant. 
Grguy Body Weight IgjL 
KC 505.8 + 11,6 
VMH 505,0 + 44, 5 
OVX 365, 8 + 16,7 
DLT 347, 8 + 10,0 
FF 312.0 + 21,7 
5,7-DHT 311,6 + 8,5 
NWRA 301.0 17,6 
DSP 291,5 + 9, 3 
Comparisons 
KC versus 
VMM ns 
OVX .01 
DLT ,01 
FF ,01 
5,7-DHT .01 
NWRA .01 
DEP ,01 
VMM versus 
OVX .01 
DLT ,01 
FF ,01 
5,7-DHT ,01 
NWRA ,01 
DEP .01 
OVX versus 
DLT u s  
FF ,01 
5,7-DHT ,01 
NWRA ,01 
DEP ,01 
DLT versus 
FF , 05 
5,7-DHT ,05 
NWRA ,01 
DEP .01 
FF versus 
5,7-DHT ns 
NWRA ns 
DEP ns 
5,7-DHT versus 
NWRA ns 
DEP ns 
NWRA versus 
DEP ns 
Figure 6, Group mean food intakes of animals allowed ad 
libitum access to the wet mash diet after the 
end of naloxone testing. Group ns are shown 
in the key. 
Groups (see pp 9-10 for further explanation); 
DEP -- deprived to 75% of normal weight 
DLT -- dorsolateral tegmental lesion 
5,7-DHT -- intraventricular 
5,7-dihydroxytryptamine 
FF -- free feeding 
KC -- hypothalamic knife cut 
NWRA — normal weight, restricted access 
OVX — ovariectomy 
VHH -- ventromedial hypothalamic lesion. 
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Table 6. Main effect of group on 24-hour wet mash food 
intakes + S. E. (g). See text for abbreviations. 
Results of statistical comparisons are shown 
beneath the data: numbers are p values, ns means 
not significant. 
Group Food Intake ial 
KC 144.6 + 2.5 
VMH 140.3 + 2.9 
DLT 90.9 + 2.3 
OVX 83.4 + 1.8 
5,7-DHT 79.9 + 1.4 
DEP 70.8 + 1.7 
NWRA 68.9 + 2.1 
FF 68.6 + 1.3 
Comparisons 
KC versus OVX versus 
VMH ns 5,7-DHT ns 
DLT .01 DEP ns 
OVX .01 NWRA .05 
5,7-DHT .01 FF .05 
DEP .01 
NWRA .01 
FF .01 
5,7-DHT versus 
VMH versus DEP ns 
DLT .01 NWRA ns 
OVX .01 FF ns 
5,7-DHT .01 
DEP .01 
NWRA .01 
FF .01 DEP versus 
NWRA ns 
DLT versus Ff ns 
OVX ns 
5,7-DHT ns 
DEP .01 
NWRA .01 NWRA versus 
FF .01 FF ns 
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Discussion 
Effects of naloxone on food intake 
Naloxone decreased food intake in a dose-related manner. 
The effect of naloxone was not different among the groups; 
that is, the feeding behavior of no group was more or less 
affected by naloxone than was the feeding behavior of the 
control (NMRA) group. 
Three possible reasons for the failure to find a 
differential effect of naloxone on feeding among the surgical 
groups are immediately apparent. The first, of course, is 
that no such effect may actually exist for the surgical 
treatments included in this experiment. This may indeed be 
the case, although one experiment reporting negative results 
is not a strong confirmation of this possibility. 
A second possibility is that the doses of naloxone used 
(0.5, 1.8, 6.8, and 25.0 mg/kg) are not doses which would 
show this effect, and that lower or higher doses are 
required. There are reasons to think, however, that this is 
not the case. First, the lowest dose of naloxone used in 
this experiment did not cause a significant reduction in food 
intake for any group; the possibility that the lowest dose 
was too large to show differential effects on groups must 
therefore be rejected. It is possible that the largest dose 
(25.0 mg/kg) was not large enough to show group differences 
in naloxone sensitivity. This argument is countered. 
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however, by the fact that 25.0 mg/kg is the largest dose of 
naloxone that has been used to suppress feeding in any 
reported experiment. Further, this dose of naloxone may 
inhibit feeding, at least in part, by producing an aversive 
state within the animal. Since the present work was begun, 
Frenk and Rogers (1979) have reported that a single injection 
of 10 mg/kg (ip) naloxone can be used to establish a 
conditioned taste aversion in the rat. The 25.0 mg/kg dose 
of naloxone used here, then, is greater than the range in 
which purely specific effects of naloxone on feeding can be 
observed. The doses Margules et al. (1978) used to obtain 
greater than control suppression of feeding in genetically 
obese rats were 0.5 and 1.0 mg/kg; doses higher than 1.0 
mg/kg were not used. Given the known range of effective 
doses (0.5 to 1.0 mg/kg), it is conceivable that the doses 
used in this experiment might fall entirely outside the 
effective range (i.e., 0.5 was too low in this case, and 1.8 
too high). While conceivable, however, such an explanation 
is not appealing, since it would require any differential 
effect to appear and disappear within a narrow dose range. 
The third possible reason for the failure to find 
differential effects of naloxone among the surgical 
treatments in this experiment may lie in the body composition 
of the animals, Margules et al, (1978) made no attempt to 
control the body weights of the genetically obese mice and 
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rats used in their work. The genetically obese rats weighed 
58% to 178% more than did their lean littermate controls. In 
the present experiment all rats (except DEP) were maintained 
at the same percentage of their presurgical body weights. If 
the animals used in the present experiment had been allowed 
to gain weight freely, differential effects of naloxone on 
feeding might have been found. This possibility will be 
further discussed below. 
A key question in evaluating the role of endogenous 
opioids in the regulation of feeding behavior is whether the 
effect of naloxone in suppressing food intake is central, 
peripheral, or perhaps both central and peripheral. A basis 
exists for naloxone suppression of feeding by a peripheral 
mechanism. Ipp et al. (1978) have shown that D-END causes 
insulin release from pancreatic islets in vitro; this effect 
is blocked by naloxone. A number of studies have shown that 
exogenous insulin can stimulate food intake and induce 
obesity (e.g. Hoebel & T.eitelbaum, 1966). Naloxone, then, 
could block or depress B-END-stimulated insulin release at 
the pancreas, thus inhibiting a known stimulus to feeding and 
obesity development, 
A reasonable basis for naloxone suppression of feeding 
by central mechanisms also exists. Both intrahypothalamic 
(Grandison 6 Guidotti, 1977) and intraventricular (Kenny et 
al., 1978) administration of 3-END elicit feeding. The 
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feeding effect of intrahypothalamic B-END is blocked by 
naloxone, (Naloxone effects on feeding behavior induced by 
intraventricular administration of B-END have not been 
tested). Further, B-END is found in brain areas associated 
with feeding, including the medial and ventral hypothalamus 
(Bloom, Bossier, Battenberg, Bayon, French, Henriksen, 
Siggins, Segal, Browne, Ling, G Guillemin, 1978). These 
findings suggest that central B-END feeding mechanisms may 
exist. Systemicaily administered naloxone could suppress 
feeding by antagonizing central B-END mechanisms involved in 
feeding. 
A complicating factor (as if one were needed) is that 
pituitary hormones, including B-END, may be directly 
transported from the pituitary to the brain by the pituitary 
venous drainage (Bergland & Page, 1979). Presumably, these 
hormones would have effects in the brain. Peripherally 
released (pituitary) B-END, then, could affect feeding by 
both central and peripheral mechanisms. Either or both of 
these mechanisms might be synergistic, antagonistic, or 
unrelated to the feeding effects of centrally released B-END. 
Naloxone, then, could affect feeding by inhibiting central 
and/or peripheral effects of pituitary B-END, and/or by 
inhibiting the effects of centrally released B-END. At 
present there appears to be no way to determine whether the 
inhibiting effect of naloxone on food intake is central or 
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peripheral. An opiate antagonist that does not penetrate the 
blood-brain barrier would be most useful in resolving this 
question, but none seems to exist. 
The preceding discussion assumes that the effects of 
naloxone are specific to opiate-activated feeding systems. 
This assumption is not unchallengeable. As indicated 
earlier, recent work (Freak & Rogers, 1979) shows that one 
10,0 mg/kg dose of naloxone is sufficient to condition a 
taste aversion in rats. It is possible, then, that higher 
(around 10,0 mg/kg and larger) doses of naloxone may suppress 
feeding simply by their noxious consequences, not by any 
effect specific to feeding systems. 
The effects of lower doses of naloxone on food intake 
probably cannot be ascribed to aversive consequences of 
naloxone treatment. Frenk and Sogers (1979) found that 0,1 
mg/kg naloxone was not sufficient to condition a taste 
aversion in rats. Further, LeBlanc and Cappell (1975) were 
not able to condition a taste aversion with naloxone at doses 
of 0.48, 1.44, or 4.32 mg/kg, even though six conditioning 
trials were used. 
Even though the effects of low doses of naloxone on 
feeding behavior are probably not due to aversive states, it 
is still not clear that naloxone acts specifically on feeding 
mechanisms, Frenk and Rogers (1979) observed that 1,0 mg/kg 
naloxone inhibits water intake in rats deprived of water for 
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23 hours, as well as inhibiting food intake in rats deprived 
of food for the same amount of time. In fact, as little as 
0.1 mg/kg naloxone suppressed water intake of 12-hour water 
deprived rats. Frenk and Rogers (1979) interpreted these 
findings as consistent with a hypothesis postulating 
opioid-mediated drive reduction systems (Belluzzi & Stein, 
1977), According to this hypothesis, naloxone would inhibit 
feeding and drinking behaviors by blocking the normal drive 
reduction resulting from these consummatory behaviors. Drive 
reduction would be blocked because naloxone would inhibit the 
effect of opioids released by these behaviors. According to 
Frenk and Rogers (1979), these behaviors would be inhibited 
because they were no longer as rewarding as previously. 
Frenk and Rogers' (1979) interpretation of the mechanism 
of naloxone's effect on food intake may provide an alternate 
interpretation for the data of Margules et al. (1978), 
Margules et al. (1978) reported that naloxone had a greater 
effect on the food intake of genetically obese rats than on 
the food intake of lean litterraates, Margules et al. (1978) 
suggested that the enhanced sensitivity of genetically obese 
rats was related to the increased concentrations of pituitary 
B-END in these animals. It is possible, however, that the 
increased naloxone sensitivity of genetically obese rats 
might be due simply to obesity. 
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Food intakes of obese rats are more easily suppressed by 
dietary adulteration than are the food intakes of normals 
(Mailer, 1964; Sclafani & Springer, 1976). Further, obese 
rats are less willing to work for food than normal weight 
rats (Sclafani 6 Springer, 1976), These observations could 
be interpreted as showing that obese rats have lower drive 
strengths for food than do normal rats under the same 
conditions. If naloxone inhibits food intake by making the 
consumption of food less rewarding, it might be reasonable to 
expect obese rats to be more sensitive to naloxone than 
normal rats. For obese rats, the consumption of food is 
already less strongly motivated than for normals, and 
therefore less rewarding. Further suppression of reward by 
naloxone might be evidenced in obese animals as a greater 
sensitivity to the effect of naloxone on feeding than is 
manifested by normal animals. 
The idea that naloxone might differentially affect 
feeding in obese animals does not rule out the possibility 
that naloxone may also act directly on feeding-specific 
mechanisms involving opiate receptors. Central injections of 
B-END do, after all, stimulate feeding in normal weight 
animals, and this effect is blocked by naloxone (Grandison & 
Guidotti, 1977; Kenny et al,, 1970). Further, the opiate 
antagonist methadone injected peripherally stimulates feeding 
(Holtzman, 1975), Methadone, B-END, and naloxone are all 
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known to interact largely with the same (opiate) receptors. 
EfEeçts_of_suTaiç^l_treatmeat_and_diet_gn_2ituitarY 
beta-endorphin-like immunoreactivity concentrations 
The lack of a differential effect of naloxone among 
surgical groups may he more informative when considered in 
light of the assay data. Pituitary B-ENDLI concentrations 
were substantially lower in knife cut rats (68% of the mean 
of all other groups). If pituitary B-END is truly important 
in the regulation of feeding behavior, then the feeding of 
animals having elevated pituitary B-END concentrations might 
be more sensitive to naloxone antagonism. Further, the 
intakes of animals with decreased pituitary B-END 
concentrations might be less sensitive to naloxone 
antagonism. The report of Margules et al. (1978) that 
genetically obese mice and rats have both elevated pituitary 
B-END levels and increased sensivity to the feeding effects 
of naloxone lends support to this notion. However, in this 
experiment knife cut rats had much lower than normal 
concentrations of pituitary B-ENDLI, but were not less 
affected by naloxone than were other groups. The data from 
the knife cut rats, then, are contrary to the expectation of 
decreased naloxone sensitivity in rats with decreased 
pituitary B-END concentrations. It should be emphasized here 
that knife cut rats showed no trend which might differentiate 
their feeding responses to naloxone from those of the other 
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groups. The lack of a significant difference between knife 
cut and other groups does not appear to be due simply to 
excessive within group variance. 
The significance of the substantially lowered (68%) 
B-ENDLI concentrations in knife cut rats is not immediately 
apparent. It is also difficult to resolve with the finding 
that VMH-lesioned rats had normal concentrations of pituitary 
B-ENDLI, since the feeding syndromes produced by these cuts 
and lesions are basically quite similar, although not 
identical (e.g. Paters, Wellman, & Gunion, 1979). This 
unexpected dissimilarity between knife cut and VMH syndromes 
may be related to another unexpected dissimilarity recently 
observed by Bray, Sclafani, and Novin (Note 1) . Bray et al. 
(Note 1) found that knife cut rats held at normal body weight 
were not hyperinsulinemic. This is in marked contrast to the 
typical finding that VMM rats are hyperinsulinemic under 
these conditions (Friedman S Strieker, 1976). A possible 
link between the lack of hyperinsulinemia (Bray et al., 
Note 1) and the lowered pituitary concentration of B-ENDLI 
in knife cut rats may be found in the work of Ipp et al. 
(1978). Ipp et al, (1978) reported that B-END causes release 
of insulin from pancreatic islets in vitro, suggesting that 
B-END is a regulator of insulin secretion. It may be, then, 
that the lower than normal pituitary B-ENDLI concentration of 
knife cut rats adversely affects insulin synthesis and/or 
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release in these animals. It would be interesting to know if 
B-END has a trophic effect on the islets of Langerhans. 
In evaluating the role of pituitary B-END in hyperphagia 
and obesity development, it may be worthwhile to further 
examine the data of Margules et al. (1978) in conjunction 
with the data reported here. Genetically obese rats 
(Margules et al., 1978), VMH-lesioned rats, DLT-lesioned 
rats, and knife cut rats all eat more than do normal animals, 
and will all weigh more than normals if allowed to eat 
freely. Pituitary D-END concentration is normal in VMH and 
DLT rats, substantially elevated in genetically obese rats 
(75%), and substantially depressed in knife cut rats (68%). 
These comparisons strongly suggest that there is no necessary 
link between pituitary B-END concentrations and feeding 
activity. It may be that genetic obesity is indeed due to 
elevated pituitary B-END concentrations, as suggested by the 
data of Margules et al. (1978); however, it certainly appears 
that not all overeating/obesity syndromes are associated with 
elevated pituitary B-END concentrations. 
Regression analysis showed that diet had a statistically 
significant effect on pituitary B-ENDLI concentration, with 
animals restricted to the pellet diet showing slightly (11%) 
lower concentrations of pituitary B-ENDLI than animals 
allowed to feed freely on the wet mash diet. This small 
difference is most likely an effect of diet per se rather 
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than body weight or feeding regimen. FF rats maintained on 
pellets (which always had free access to food) had 
concentrations of pituitary B-ENDLI 14% lower than those of 
FF rats switched to the wet mash diet. Why the wet mash diet 
should alter pituitary B-ENDLI concentration is not clear. 
Food intake, body weight, and the wet mash diet 
The changes in body weight and food intake during 
maintenance on the wet mash diet were generally as expected. 
Both VMH and KC groups increased their food intakes 
substantially (204% and 210%, respectively, of NHRA intake). 
By day 36 both these groups weighed 168% of the weight of 
group NWRA. Groups DLT and OVX also ate more than group NWRA 
(13255 and 121%, respectively, of NWRA intake), and weighed 
more than NWRA on day 36 (111% and 114%, respectively, of 
NWRA). Also as expected, neither group FF or DEP ate more 
than NWRA over the 36 days, and neither of these groups 
weighed significantly more or less than NWHA on day 36. 
The feeding and weight changes of group 5,7-DHT were not 
as expected. Rats treated with 5,7-DHT have previously been 
shown to overeat and gain weight when allowed free access to 
either a pellet (Sailer & Strieker, 1976) or high fat 
(Luttmers, 1978) diet. In this experiment 5,7-DHT rats did 
not overeat or gain weight to greater than control (NWRA) 
levels when allowed free access to a wet mash diet. This was 
surprising, since these rats ate more than NWRA rats during 
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restricted access testing using pellets. Since 5,7-DHT rats 
will overeat under ad libitum conditions, it is most likely 
that the wet mash diet was the proximate cause of the failure 
to overeat. Why this should be is not clear. In general, 
wet mash diets induce larger weight gains than pellet diets 
(e.g. Peters, Wellman, & Gunion, 1979), and the wet mash diet 
was used here for that reason. It may be that 5,7-DHT rats 
have trouble eating wet mash. During this experiment 5,7-DHI 
rats left large amounts of spillage beneath their cages 
during restricted access testing with pellets, Luttmers 
(Note 2) also noted greater than normal spillage under 
5,7-DHT cages when a high fat diet was used. The spillage 
here was composed of larger "shreds" of food pellets, rather 
than the crumb- or dust-like spillage of all other groups in 
this experiment. This shredding of food may indicate 
physical difficulty in biting, chewing, or some other aspect 
of food handling. Alternatively, the large water content of 
the wet mash diet may pose difficulties for 5,7-DHT rats. 
Central mechanisms are most certainly involved in the 
regulation of body water and electrolyte balance. Treatment 
with 5,7-DHT may damage one or some of these mechanisms, 
making it simply impossible for 5,7-DHT treated rats to 
accommodate very large water intakes. 
One interesting finding of this experiment was that rats 
given intraventricular injection of 5,7-DHT did overeat 
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during the restricted access testing periods, which occurred 
during the dark portion of the daily light/dark cycle. Hats 
given such treatment and allowed continuous access to food 
have been shown to overeat only during the light portion of 
the daily cycle, and not during the dark (Sailer 6 Strieker, 
1976). The results of the present experiment suggest that 
this circadian rhythmicity may be altered by restricted 
access feeding. These results are also interesting in light 
of some failures to replicate the initial report of Sailer 
and Strieker (1976). Both Coscina and Hoebel (Coscina, 1978; 
Hoebel, Zemlan, Trulson, MacKenzie, DuCret, S Norelli, 1978) 
reported that injections of 5,7-DHT did not result in 
increased feeding or weight gain. Luttmers (1978) did 
replicate the findings of Sailer and Strieker (1976), and may 
be the only replication to date. 
Summary 
None of the experimental hyperphagia/obesity syndromes 
examined here was more or less sensitive than normal to the 
food intake suppressing effect of the opiate antagonist 
naloxone. Eats with hypothalamic parasagittal knife cuts had 
substantially lowered concentrations of pituitary B-ENDLI, 
while other hyperphagia/obesity syndromes examined did not 
show altered B-ENDLI levels. Obesity did not significantly 
alter pituitary B-ENDLI concentrations. In conjunction with 
data from genetically obese rats, these data indicate that 
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iGvated, or even merely altered, concentrations of pituitary 
-END are not necessarily related to hyperphagia and obesity. 
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AE£endixi Literatujçe_Review 
Four years ago a new class of brain penta-peptides 
having opioid properties, the enkephalins, was discovered 
(Hughes, Smith, Kosterlitz, Fothergill, Morgan, & Morris, 
1 975) . With this discovery it was observed that one of these 
penta-peptides was found in beta-iipotropin (B-LPH) , a 
polypeptide previously isolated from camel pituitary and 
sequenced (Li G Chung, 1976). It was soon found that another 
closely related class of polypeptide also existed (Ling, 
Burgus, 6 Guillemin, 1976). The members of this class, the 
endorphins, were between 16 and 31 amino acids long, were 
also contained within the sequence of B-LPH, and themselves 
all contained one of the enkephalins (met-enkephalin) as 
their five N-terminal amino acids. 
Although these substances were initially investigated 
with regard to their opioid-like analgesic properties (e.g. 
Cox, Goldstein, 6 Li, 1976; Graf, Szekely, Sonai, 
Dunai-Kovacs, & Bajusz, 1976), other effects have been 
examined. The enkephalins and endorphins have now been 
investigated with regard to mental illness (Vereby, Volavka, 
& Clouet, 1978: Watson, àkil. Berger, & Barchas, 1979), 
sexual behavior (Gessa, Paglietti, & Quarantotti, 1979), open 
field activity (Veith, Sandman, Walker, Coy, S Kastin, 1978), 
stress responses (Guillemin, Vargo, Bossier, Minick, Ling, 
Rivier, Vale, S Bloom, 1977), the regulation of feeding 
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(Kenny, McKay, Woods, & Williams, 1978; Margules, Hoisset, 
Lewis, Shibuya 6 Pert, 1978), and digestive activities 
(Hughes et al., 1975; Jacques, 1977; Konturek, Pawlik, Malus, 
Coy, & Schally, 1978; Konturek, Tasler, Cieszkowski, Jaworek, 
Coy, & Schally, 1978), The feeding and digestive effects are 
of interest here. Before these effects can be described, 
however, it is necessary to briefly differentiate among the 
opioid peptides, and to describe their general distribution 
in the body. 
lioâI£tàesi^_Mâ_âistribution 
Biosynthesis. The interrelationships among the 
enkephalins, endorphins, and their precursors are complex. 
The essential relationships will be outlined here. 
The parent of at least some of these substances is a 
31,000 dalton glycoprotein that has been termed 
"proopiocortin" (Mains, Eipper, & Ling, 1977; Rubinstein, 
Stein, & Udenfriend, 1978). This term is quite appropriate, 
since this molecule is the parent to adrenocorticotropic 
hormone (ACTH) as well as some of tJie opioid peptides. 
Proopiocortin is apparently fragmented to form ACTH and 
B-LPH. It was initially thought that B-LPH, in turn, was 
fragmented to directly form the endorphins; alpha-endorphin 
(B-LPH 61-76), beta-endorphin (B-LPH 61-91; B-END), and 
gamma-endorphin (B-LPH 61-77). Although B-END does appear 
to be a true product of B-LPH degradation (Crine, Benjannet, 
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Seidah, Lis, & Chretien, 1977; Graf, Cseh, Barat, Ronai, 
Szekeiy, Kenessey, 6 Bajusz, 1977), data now indicate that 
alph-endorphin may be an extraction artifact (Bossier, Bayon, 
Vargo, Ling, Guillemin, 6 Bloom, 1977). It also appears that 
gamma-endorphin is a degradation product of B-END (Graf et 
al., 1977), rather than a direct product of B-LPH. 
The sequence of met-enkephalin, one of the two known 
naturally occurring opioid penta-peptides, is found as the 
N-terminal five amino acid sequence of B-END (B-LPH 61-65; 
Tyr-Gly-Gly-Phe-Met; Hughes et al., 1975). There is very 
suggestive evidence, however, that met-enkephalin is not 
normally formed iutracellularly by B-END degradation (Bloom, 
Battenberg, Bossier, Ling, & Guillemin, 1978; DiGuilo, 
Lutold, Fratta, Yang, & Costa, 1978; Polak, Bloom, Sullivan, 
Facer, & Pearse, 1977; Schulz, Wuster, Simantov, Snyder, & 
Herz, 1977; Watson, Akil, Richard, S Barchas, 1978) , although 
it may be formed in that manner extracellularly (Austen, 
Smyth, & Snell, 1977). The otlier enkephalin, leu-enkephalin 
(Tyr-Gly-Gly-Phe-Leu; Hughes et al., 1975) is not found in 
the sequence of any known portions or products of 
proopiocortin. It is thought that both enkephalins may be 
synthesized by some other route (Watson, Barchas, & Li, 1977; 
Watson et al., 1978). 
Distribution. B-END has been located in both brain and 
pituitary (Bloom, Bossier, Battenberg, Bayon, French, 
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Henciksen, Siggins, Segal, Browne, Ling, & Guilliiinin, 1978) . 
In brain, B-END is found in greatest amounts in the 
hypothalamus, with lesser concentrations in the septum, 
midbrain, and medulla-pons. Hypothalamic neurons containing 
B-END have been located by immunohistofluorescence along the 
third ventricle within the periventricular and arcuate 
nuclei, and along the base of the brain moving laterally from 
the arcuate nucleus, and terminating ventral to the lateral 
hypothalamic area. Some B-END neurons are found along the 
thalamic third ventricle, and within the thalamic 
paraventricular nucleus (Bloom, Bossier, Battenberg, Bayon, 
French, Henriksen, Siggins, Segal, Browne, Ling, 6 Guillemin, 
1978) . 
B-LPH, the apparent precursor to B-END, has been located 
in the same regions as B-END; additionally, it has been foujid 
that the locus coeruleus is heavily invested by B-LPH 
neurons, as is the central gray around the cerebral aqueduct, 
B-LPH has also been located in the zona incerta, ansa 
lenticularis, stria terminalis, and medial amygdala. 
Moderate investment of B-LPH neurons is found in the 
substantia nigra zona compacta (Watson et al., 1977). 
Pituitary B-END is found in highest concentrations in 
the pars intermedia (1500 ng/g tissue, rat), with pars 
distalis showing some B-END (269 ng/g tissue, rat). No B-END 
has been found in pars nervosa (Bloom, Bossier, Battenberg, 
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Bayon, French, Henriksen, Siggins, Segal, Browne, Ling, 6 
Guilleinin, 1978). This quantitative work correlates well 
with iramunohistofluorescence work showing that all pars 
intermedia cells contain B-END/B-LPH, while scattered 
B-END/B-LPH cells are seen in the pars distalis (Pelletier, 
Leclerc, Labrie, Cote, Chretien, & Lis, 1977; Watson et al., 
1978). It has also been shown that B-END, B-LPH, and 
gamma-endorphin are synthesized in bovine pars intermedia in 
vitro (Crine et al., 1977). 
Neither of the enkephalins have been found in pituitary 
tissue (Bloom, Bossier, Battenberg, Bayon, French, HenriJcsen, 
S logins, Segal, Browne, Ling, & Guillemin, 1978; Watson et 
al., 1976). The enkephalins do occur in brain, but show a 
distribution distinctly different from B-END and B-LPH 
(Bloom, Rossier, Battenberg, Bayon, French, Henriksen, 
Siggins, Segal, Browne, Ling, & Guillemin, 1978; Johansson, 
Hokfelt, Elde, Schultzberg, 6 Terenius, 1978; see also Watson 
et al., 1978). The enkephalins have also been found in gut, 
primarily in the antrum and the upper small intestine. In 
the antrum enkephalin is found in gastrin-secreting cells, 
but not in cells secreting other peptides (e.g. somatostatin) 
(Polak et al., 1977). In the small intestine enkephalin is 
found both within the myenteric plexus and within the 
circular muscle (Johansson et al., 1978); it has been shown 
that enkephalin is released in vitro from electrically 
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stimulated myenteric plexus-longitudinal muscle preparations 
(Hughes, Kosterlitz, & Sosa, 1978; Schulz et al,, 1977). 
Enkephalin has also been found in the pancreas, gallbladder, 
and colon (Polak et al., 1977). It should be noted that the 
physical location of the enkephalins in the gut corresponds 
well to their apparent physiological effects (see below). 
B-END and B-LPH have not been found in the gut, except in a 
few cases of ectopic ACTH secreting tumors (Hirata, 
Matsukura, Imura, Nakamura, & Tanaka, 1976; see also 
Guillemin et al., 1977). 
Role of opioid peptides in the physiology and behavior 
of_food_intake_aad_digestign 
Enkephalins. The enkephalins have interesting effects 
in the gut. Met-enkephalin increases the rate of gastric 
blood flow when tested alone, and enhances gastric acid 
secretion induced by histamine (Konturek, Pawlik, Walus, Coy, 
S Schally, 1978). As stated earlier, enkephalin has been 
found in antral gastrin secreting cells (Polak et al., 1977); 
such a close relationship with gastrin, both physically and 
physiologically, suggests the two substances may act 
synergistically in the control of gastric acid secretion. 
The location of enkephalin in the intestine (Johansson 
et al., 1978) may be related to its effect in inhibiting 
contraction of electrically (Hughes et al., 1975) or 
chemically (Jacques, 1977) stimulated myenteric 
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plexus-longitudinal muscle preparations. Likewise, location 
of enkephalin in the pancreas may be related to the effect of 
exogenous enkephalin in decreasing the bicarbonate and 
exocrine protein secretion of that organ (Konturek, Tasler, 
Cieszkowski, Jaworek, Coy, 8 Schally, 1978). 
Aside from these effects on gut physiology, the 
enkephalins have not been shown to have an effect, or 
potential effect, on food intake. 
Endorphins. Indirect evidence for the role of a 
pituitary factor in the regulation of feeding, possibly 
B-END, comes from several lines of research. 
Beloff-Chain and colleagues have shown that a factor 
released from mouse pituitary in vitro causes release of 
insulin from isolated pancreatic islets (Beloff-Chain, 
Edwardson, f- Hawthorn, 1975; Beloff-Chain, Edwardson, & 
Hawthorn, 1977; Beloff-Chain S Hawthorn, 1976; Beloff-Chain, 
Hawthorn, 5 Green, 1975). Perifusate from pituitaries of 
genetically obese mice causes a greater release of insulin 
than does perifusate of normal mouse pituitaries when normal 
islets are used (tieloff-Chain, hawthorn, & Green, 1975) . 
This pituitary factor apparently affects a quickly mobilized 
insulin pool, and pancreatic islets from genetically obese 
mice appear refractory to this factor (Beloff-Chain & 
Hawthorn, 1976). 
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It is also known that hypophysectoraized rats have a 
decreased insulin response to glucose challenge (Malaisse, 
Malaisse-Lagae, King, S Wright, 1968; Handle 6 Young, 1956). 
Such a decreased insulin response suggests that the presence 
of some pituitary factor(s) is (are) necessary for the normal 
maintenance of insulin synthesis and/or release. Whether 
this effect is entirely due to any of the previously 
identified pituitary hormones is not clear (cf. Malaisse et 
al., 1968, and Handle 6 Young, 1956). Beloff-Chain 
(Beloff-Chain et al., 1977) has suggested that this 
pituitary factor is corticotropin-like intermediate lobe 
peptide (CLIP; ACTH 18-39), since (1) CLIP and ACTH 17-39 
cause insulin release in vitro (ACTH does not); (2) the 
unknown pituitary factor Beloff-Chain found to cause insulin 
release was found only in pars intermedia perifusate; and (3) 
CLIP is found in the pars intermedia (Lowry, Silman 6 Hope, 
1977). While CLIP would thus appear a likely candidate, it 
must be noted that CLIP may not exist under normal 
physiological conditions, except during pregnancy (Lowry et 
al., 1977). As noted in a previous section, B-END is also 
found in the pars intermedia (Bloom, Rossier, Battenberg, 
Bayon, French, Henriksen, Siggins, Segal, Browne, Ling, & 
Guillemin, 1978), and in fact exists there in the highest 
concentration of any tissue yet examined quantitatively. 
B-END, then, might be a candidate for the insulin releasing 
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factor of Beloff-Chain. Recently Ipp, Dobbs, and Unger 
(1978) reported data supporting this possibility. They 
reported that B-END can cause release of insulin from 
pancreatic islets in vitro. This finding suggests that 
elevated pituitary B-END and a resultant hyperinsulinemia may 
play an important role in genetic obesity. 
Direct evidence linking pituitary B-END to the 
regulation of food intake comes from a recent study of 
genetically obese mice and rats (Margules et al., 1978). 
Wargules found that genetically obese rats and mice have 
pituitary B-END levels 75% and 80%, respectively, above those 
of lean littermares. Further, it was found that the 
exaggerated food intake of these animals was antagonized to a 
greater degree than that of lean littermates by injection of 
the opiate antagonist naloxone. In rats every dose tested 
(0,25 to 1,0 mg/kg ip) produced a greater percent reduction 
of food intake in obese animals than their lean littermates. 
Similar results were obtained in the genetically obese mice. 
Data suggesting that some substance that interacts with 
opiate receptors is involved in the normal regulation of food 
intake has been obtained by Holtzman (1974, 1975) and 
Margules et al. (1978). Holtzman (1974) showed that naloxone 
produced a dose-dependent decrease in intake of regular 
laboratory food pellets in normal rats, finding that a dose 
of 10 mg/kg practically abolished food intake (7% of saline 
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control). Holtzman (1975) showed that naloxone, naltrexone, 
and nalorphine, all opiate antagonists, reduced consumption 
of sweetened Enfamil in a dose-dependent manner. Further, 
the opiate agonist methadone caused an increase in intake 
when given at a low dose (0.1 mg/kg). These apparently 
clear-cut results are tempered, however, by the finding that 
neither morphine nor cyclazocine, two opiate agonists, caused 
an increase in intake at any dose tested. Margules et al. 
(1978) found naloxone decreased food intake in lean rats and 
mice as well as in genetically obese ones, but that lean 
rodents required higher doses. 
Direct central manipulations have also yielded data 
indicating a possible role for B-END in the regulation of 
feeding. Kenny et al. (1978) found that injection of 200 ng 
B-FND into the lateral ventricle of the rat increased 
comsumption of sweetened milk. This effect was not seen with 
cholecystokinin, substance P, or neurotensin. Peripheral 
injection of the same dose was without effect. Grandison and 
Guidotti (1977) found that intrahypothalamic injection of 
1.46 nm of B-END caused increased intake of laboratory chow. 
The feeding effects of B-END were blocked by subsequent 
intrahypothalamic injection of naloxone, Grandison and 
Guidotti (1977) also reported data suggesting that 
GABA-receptive neurons serve as mediators for feeding due to 
intrahypothalamic application of either B-END or 
75 
nore pinephrine. 
Summary 
1. B-END is known to directly stimulate feeding when 
injected centrally, and neurons containing B-END 
exist in or near these areas, 
2. A mechanism exists for peripheral (pituitary) B-END 
to cause feeding by direct stimulation of insulin 
release. 
3. Genetically obese rats and mice have increased 
levels of pituitary B-END. 
4. Naloxone, which blocks B-END effects by competitive 
inhibition : 
a. suppresses feeding in normal animals; 
b. suppresses intake in animals feeding due to 
B-END injection; 
c. is more effective in suppressing feeding of 
genetically obese rats and mice than in their 
lean littermates. 
5. Enkephalins may well play a role or roles in the 
local regulation of gut activities, but at present 
do not otherwise seem to be involved in feeding or 
related activities. 
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